Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-1117567 in Mild to Moderate Alzheimer's Disease
NCT07832383Phase 2Not yet recruiting
- Sponsor
- Neurocrine Biosciences
- Start
- Oct 2026
- Primary completion
- May 2028
01
Overview
Phase 2, randomised trial of NBI-1117567 in Alzheimer's disease (AD) (3 arms), sponsored by Neurocrine Biosciences. Primary endpoint: Neuropsychological Test Battery Composite at Day 85. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
NBI-1117567
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07832383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832383.